Status:
COMPLETED
Growth Hormone and Endothelial Function in Children
Lead Sponsor:
Ohio State University
Collaborating Sponsors:
Nationwide Children's Hospital
Conditions:
Growth Hormone Deficiency
Panhypopituitarism
Eligibility:
All Genders
8-18 years
Phase:
PHASE4
Brief Summary
Objective: This study is designed to determine whether growth hormone treatment in children 8 to 18 years of age alters function of the lining of the arteries. This may play a role in increasing or de...
Detailed Description
The purpose of the research is to learn more about how the lining of arteries in the body (called the endothelium) is affected by growth hormone treatment in children and adolescents. Poor function by...
Eligibility Criteria
Inclusion
- isolated growth hormone deficiency (peak growth hormone level less than 10 ng/ml in response to arginine-insulin stimulation with cortisol responses and thyroid function tests), panhypopituitarism with appropriate thyroxine (normal free T4 level) and cortisol replacement (8-12 mg/m2/day) and non classic growth hormone deficiency (growth velocity less than 5 cm/year; peak growth hormone \>10 ng/ml).
Exclusion
- Taking medications other than the appropriate hormonal replacement(L-thyroxine, cortisol, estrogen or testosterone, DDAVP)
Key Trial Info
Start Date :
January 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2007
Estimated Enrollment :
9 Patients enrolled
Trial Details
Trial ID
NCT00373386
Start Date
January 1 2005
End Date
December 1 2007
Last Update
May 30 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ohio State University
Columbus, Ohio, United States, 43210